Database Member Home
RAS Member Home
Identifying different types of Key Opinion Leaders (KOLs), segmenting them according to their influence and developing appropriate relationships along a product’s lifecycle are important initial steps to successful KOL engagement. Therefore, biopharmaceutical companies must establish the right contact frequency for visits with Key Opinion Leaders and find ways to streamline multiple touch points with KOLs to curb internal competition for their attention.
This Best Practices, LLC video provides insights around the ideal contact frequency for National KOLs and Regional KOLs, and activities that drive KOL management. It provides the best practices and insights around successful KOL engagement.
Medical Affairs leaders can use these insights to develop strategic profiling and recruitment mechanisms to identify core targets, and segment KOLs by the traits required for their needs and strategy.
Pharmaceutical companies continue to improve the effectiveness of their managed care interactions by employing specialized medical liaisons who can speak the "payer language... (ID POP-283)
Read More »
In pharma, regulatory and access restrictions have reshaped key interactions with thought leaders... (ID POP-267)
Key Opinion Leaders (KOLs) are recognized as one of the most effective avenues for building awareness in medical and scientific communities... (ID POP-253)
Pharmaceutical and life science companies rely heavily on key opinion leaders (KOLs) to improve their credibility in the marketplace... (ID PSM-235)
Pharmaceutical and medical device organizations seek strategic insights and guidance to successfully navigate the complexities of the changing healthcare landscape... (ID PSM-319)
As Medical Science Liaisons (MSLs) increasingly face restricted access to physicians and KOLs, it is important for biopharmaceutical and medical device companies to empower MSLs with new processes and tools that facilitate rapid and effective customer engagement... (ID POP-286)
The growing demand for scientific and medical data in the biopharmaceutical industry has pushed organizations to develop effective KOL engagement strategies for their field-based medical and field-based outcomes and pricing group... (ID POP-288)